N ANTHONY COLES
CIK 1197018 · CEO and Chairperson · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.11M
Companies
10
Total Filings
103
Lifetime Open-Market Net
-$78.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| REGN | Director | 1,714 | $694.59 | $1.19M | -$20.62M | 16 | 2026-01-06 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 25,928 | $44.96 | $1.17M | -$30.40M | 22 | 2024-07-03 |
| KINETA, INC./DE (YMTX) Delisted | Executive Chair | 106,239 | $13.23 | $1.41M | $0 | 3 | 2021-04-02 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | President and CEO | — | $18.07 | — | $0 | 2 | 2021-02-05 |
| MCK | Director | 0 | $888.50 | $0 | -$558.3K | 9 | 2020-08-19 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 70,000 | — | — | $0 | 3 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chairman & CEO | 131,198 | — | — | -$26.92M | 17 | 2013-06-07 |
| Campus Crest Communities, Inc. (RLD) Delisted | Director | 3,999 | — | — | $0 | 4 | 2013-05-31 |
| LH | Director | 3,008 | $306.62 | $922.3K | $0 | 4 | 2013-02-19 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | President, COO & Director | 147,638 | — | — | $0 | 7 | 2008-03-18 |
Recent Filings · Page 3 of 11
103 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-16 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$493.6K | EDGAR |
| 2023-11-09 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$585.0K | EDGAR |
| 2023-11-07 | — | Notice (144) | −50,000 | -$1.25M | EDGAR |
| 2023-11-06 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$2.18M | EDGAR |
| 2023-11-03 | — | Notice (144) | −50,000 | -$1.24M | EDGAR |
| 2023-11-02 | — | Notice (144) | −50,000 | -$1.27M | EDGAR |
| 2023-09-08 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$1.03M | EDGAR |
| 2023-09-07 | — | Notice (144) | −50,000 | -$1.21M | EDGAR |
| 2023-07-13 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$1.33M | EDGAR |
| 2023-07-11 | — | Notice (144) | −50,000 | -$1.53M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.